Patents by Inventor Vadim Gaponenko

Vadim Gaponenko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide inhibition of CCR3-mediated diseases or conditions
    Patent number: 11167012
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: November 9, 2021
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS
    Publication number: 20190374608
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Application
    Filed: July 29, 2019
    Publication date: December 12, 2019
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • Peptide inhibition of CCR3-mediated diseases or conditions
    Patent number: 10363286
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 30, 2019
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS
    Publication number: 20170304401
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 26, 2017
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • PEPTIDE-BASED STAT INHIBITOR
    Publication number: 20170204148
    Abstract: A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.
    Type: Application
    Filed: January 3, 2017
    Publication date: July 20, 2017
    Inventors: Nadya I. Tarasova, Olga Timofeeva, Vadim Gaponenko, Alan O. Perantoni, Sergey G. Tarasov, Christopher J. Michejda
  • Peptide-based stat inhibitor
    Patent number: 9540427
    Abstract: A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: January 10, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Nadya I. Tarasova, Olga Timofeeva, Vadim Gaponenko, Christopher J. Michejda, Maria Michejda, Alan O. Perantoni, Sergey G. Tarasov
  • LIPOPEPTIDE INHIBITORS OF RAS ONCOPROTEINS
    Publication number: 20160151456
    Abstract: A method of inhibiting Ras activity in a cell comprising introducing a peptide or peptidomimetic into the cell, wherein the peptide or peptidomimetic is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: Nadya I. Tarasova, Sergey G. Tarasova, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
  • Lipopeptide inhibitors of RAS oncoproteins
    Patent number: 9328142
    Abstract: The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: May 3, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, Vanderbilt University, The Board of Trustees of the University of Illinois
    Inventors: Nadya I. Tarasova, Sergey G. Tarasov, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
  • LIPOPEPTIDE INHIBITORS OF RAS ONCOPROTEINS
    Publication number: 20140135276
    Abstract: The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal ?-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same.
    Type: Application
    Filed: May 25, 2012
    Publication date: May 15, 2014
    Applicants: CALIDRIS THERAPEUTICS, LTD., The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Dep. of Health & Human Services, VANDERBILT UNIVERSITY
    Inventors: Nadya I. Tarasova, Sergey G. Tarasov, Vadim Gaponenko, Joseph Kates, Alla Ivanova, Michael C. Dean
  • PEPTIDE-BASED STAT INHIBITOR
    Publication number: 20100184697
    Abstract: A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.
    Type: Application
    Filed: May 30, 2008
    Publication date: July 22, 2010
    Applicant: THE U.S OF AMERICA, AS REPRESENTED BY THE SECRETAR
    Inventors: Nadya I. Tarasova, Olga Timofeeva, Vadim Gaponenko, Christopher J. Michejda, Maria Michejda, Alan O. Perantoni, Sergey G. Tarasov